Advertisement

Topics

Takeda Recognizes ALK+ Day with Launch of tALK+ Initiative During November’s Lung Cancer Awareness Month

09:00 EST 8 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
− tALK+ Promotes the Insights, Contributions and Individuals Making a Positive Impact on the Forefronts of ALK+ Non-Small Cell Lung Cancer (NSCLC) − − Launch of ALKConnect Registry Connects and Informs Patients Li...

Other Sources for this Article

Takeda Pharmaceutical Company Limited
Amanda Loder, +1-212-259-0491
Amanda.Loder@takeda.com

NEXT ARTICLE

More From BioPortfolio on "Takeda Recognizes ALK+ Day with Launch of tALK+ Initiative During November’s Lung Cancer Awareness Month"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...